Company: AGIO
Filing Date: 2025-02-13
Form Type: 10-K
Source: 0001439222-25-000009
Chunk: 809

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-02-13
Form: 10-K
Item: Item 8
Chunk 809
---
,109 2,810 Inventory27,616 19,076 Prepaid expenses and other current assets40,165 35,021 Total current assets965,600 833,835 Marketable securities638,321 29,435 Operating lease assets42,879 54,409 Property and equipment, net11,675 15,382 Other non-current assets4,724 4,057 Total assets$1,663,199 $937,118 Liabilities and stockholders’ equityCurrent liabilities:Accounts payable$16,643 $9,780 Accrued expenses46,861 43,167 Income taxes payable871 — Operating lease liabilities16,781 15,008 Total current liabilities81,156 67,955 Operating lease liabilities, net of current portion40,207 56,988 Other non-current liabilities880 1,156 Total liabilities122,243 126,099 Commitments and contingent liabilities (Note 14)Stockholders’ equity:Preferred stock, $0.001 par value; 25,000,000 shares authorized, no shares issued and outstanding at December 31, 2024 and 2023— — Common stock, $0.001 par value; 125,000,000 shares authorized; 73,372,696 shares issued and 57,156,285 outstanding at December 31, 2024 and 72,161,489 shares issued and 55,945,078 outstanding at December 31, 202373 72 Additional paid-in capital2,493,811 2,436,523 Accumulated other comprehensive loss(1,518)(441)Accumulated deficit(148,924)(822,649)Treasury stock, at cost (16,216,411 shares at December 31, 2024 and December 31, 2023)(802,486)(802,486)Total stockholders’ equity1,540,956 811,019 Total liabilities and stockholders’ equity$1,663,199 $937,118 

See accompanying Notes to Consolidated Financial Statements.

F-4

Agios Pharmaceuticals, Inc.

Consolidated Statements of Operations

 (In thousands, except share and per share data) Years Ended December 31:202420232022Revenues:Product revenue, net$36,498 $26,823 $11,740